Plain-English translation of NCT04778839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new formulation of a standard cancer drug, in patients with advanced solid tumors. The study happens in two parts: first, researchers will gradually increase the dose to find the safest and most effective amount, and then they will test this medication in larger groups of patients with different types of cancer (breast, ovarian, lung, and stomach cancer) to confirm it is safe and works well.
Standard paclitaxel has been used for decades to treat cancer, but researchers want to develop a better formulation that may work more effectively or cause fewer side effects. This trial will help determine if this new form of the medication is a promising option for patients with advanced cancers who have limited treatment choices.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive intravenous infusions of the medication over a 3-hour period, with each treatment cycle lasting 3 weeks. Depending on which part of the study you are in, you may receive gradually increasing doses or a set dose determined from the first part of the study. You will have regular blood tests and imaging scans to monitor how your body is responding and to check for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
First Affiliated Hospital of Zhejiang University
Collaborators
Hangzhou Dihua Biotechnology Co., LTD.
Enrollment target
~98 participants
Started
March 2021
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
jian liu, master
The First Affiliated Hospital,ZheJiang Univercity
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.